García-Vallejo JJ - Search Results

1

Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines.

García-Vallejo JJ, Unger WW, Kalay H, van Kooyk Y. García-Vallejo JJ, et al. Oncoimmunology. 2013 Feb 1;2(2):e23040. doi: 10.4161/onci.23040. Oncoimmunology. 2013. PMID: 23525136 Free PMC article.

2

Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.

Singh SK, Stephani J, Schaefer M, Kalay H, García-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y. Singh SK, et al. Mol Immunol. 2009 Dec;47(2-3):164-74. doi: 10.1016/j.molimm.2009.09.026. Epub 2009 Oct 8. Mol Immunol. 2009. PMID: 19818504

3

Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.

van Kooyk Y, Unger WW, Fehres CM, Kalay H, García-Vallejo JJ. van Kooyk Y, et al. Mol Immunol. 2013 Sep;55(2):143-5. doi: 10.1016/j.molimm.2012.10.031. Epub 2012 Nov 14. Mol Immunol. 2013. PMID: 23158834 Review.

4

The physiological role of DC-SIGN: a tale of mice and men.

Garcia-Vallejo JJ, van Kooyk Y. Garcia-Vallejo JJ, et al. Trends Immunol. 2013 Oct;34(10):482-6. doi: 10.1016/j.it.2013.03.001. Epub 2013 Apr 20. Trends Immunol. 2013. PMID: 23608151 Review.

5

Understanding the biology of antigen cross-presentation for the design of vaccines against cancer.

Fehres CM, Unger WW, Garcia-Vallejo JJ, van Kooyk Y. Fehres CM, et al. Front Immunol. 2014 Apr 8;5:149. doi: 10.3389/fimmu.2014.00149. eCollection 2014. Front Immunol. 2014. PMID: 24782858 Free PMC article. Review.

6

Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.

Fehres CM, Kalay H, Bruijns SC, Musaafir SA, Ambrosini M, van Bloois L, van Vliet SJ, Storm G, Garcia-Vallejo JJ, van Kooyk Y. Fehres CM, et al. J Control Release. 2015 Apr 10;203:67-76. doi: 10.1016/j.jconrel.2015.01.040. Epub 2015 Feb 2. J Control Release. 2015. PMID: 25656175

7

Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8⁺ T cells.

Schetters STT, Jong WSP, Horrevorts SK, Kruijssen LJW, Engels S, Stolk D, Daleke-Schermerhorn MH, Garcia-Vallejo J, Houben D, Unger WWJ, den Haan JMM, Luirink J, van Kooyk Y. Schetters STT, et al. Acta Biomater. 2019 Jun;91:248-257. doi: 10.1016/j.actbio.2019.04.033. Epub 2019 Apr 17. Acta Biomater. 2019. PMID: 31003032 Free article.

8

DC-SIGN mediates adhesion and rolling of dendritic cells on primary human umbilical vein endothelial cells through LewisY antigen expressed on ICAM-2.

García-Vallejo JJ, van Liempt E, da Costa Martins P, Beckers C, van het Hof B, Gringhuis SI, Zwaginga JJ, van Dijk W, Geijtenbeek TB, van Kooyk Y, van Die I. García-Vallejo JJ, et al. Mol Immunol. 2008 Apr;45(8):2359-69. doi: 10.1016/j.molimm.2007.11.001. Epub 2007 Dec 26. Mol Immunol. 2008. PMID: 18155766

9

Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses.

van Vliet SJ, García-Vallejo JJ, van Kooyk Y. van Vliet SJ, et al. Immunol Cell Biol. 2008 Oct;86(7):580-7. doi: 10.1038/icb.2008.55. Epub 2008 Aug 5. Immunol Cell Biol. 2008. PMID: 18679407 Review.

10

TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program.

Chamorro S, García-Vallejo JJ, Unger WW, Fernandes RJ, Bruijns SC, Laban S, Roep BO, 't Hart BA, van Kooyk Y. Chamorro S, et al. J Immunol. 2009 Sep 1;183(5):2984-94. doi: 10.4049/jimmunol.0801155. Epub 2009 Jul 31. J Immunol. 2009. PMID: 19648269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters